Axsome Therapeutics, Inc.

The FDA decision on AXS-05 for Alzheimer's disease agitation, expected by April 30, represents a major near-term catalyst. CEO Herriot Tabuteau highlighted this as a key 2026 milestone, and analysts at Oppenheimer see Alzheimer's agitation approval as a primary driver of the company's growth outlook.

Regulatory outcomes remain inherently uncertain, and Axsome's Altman Z-Score of 2.8 — below the 3.0 safety threshold — signals elevated financial risk. A failed or delayed FDA decision on AXS-05 could strain the company's runway before it reaches cash flow positivity.

Axsome delivered Q4 2025 total net product revenue of $196 million, representing 65% year-over-year growth and beating analyst estimates. The company projects its current cash is sufficient to fund operations into cash flow positivity, with a 5-year revenue growth forecast of ~42%.

Despite strong revenue growth, Axsome continues to post significant losses. The company reported EPS of -$1.26, missing the consensus estimate of -$0.85 by $0.41, and analysts project -$2.45 EPS for the full current year, raising questions about the timeline and credibility of the profitability roadmap.

Multiple firms have aggressively raised price targets, with RBC Capital at $304, TD Cowen at $300, Mizuho at $310, and HC Wainwright at $290. Morgan Stanley upgraded the stock from 'reduce' to 'overweight', reflecting growing institutional conviction in Axsome's commercial and pipeline trajectory.

Despite the consensus 'Moderate Buy' rating, one analyst maintains a Sell rating, and price targets range widely from $246 (Baird) to $310 (Mizuho). A recent 5.7% single-day stock drop, attributed partly to insider selling and profit-taking, underscores meaningful uncertainty around the current valuation.